Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | FABP6 | P51161 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010660 | 0.86 | HTT (0.42) | KDM1AMAOAOPRM1OPRK1KMT2A | |
| SCHEMBL11475120 | 0.85 | OPRM1 (0.47) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| SCHEMBL11475123 | 0.85 | OPRM1 (0.47) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| SCHEMBL11456462 | 0.85 | OPRM1 (0.47) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| SCHEMBL27010664 | 0.84 | KDM4E (0.54) | IKZF2KDM1AMAOAKMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL11455194 | 0.82 | OPRM1 (0.46) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL11455195 | 0.82 | OPRM1 (0.46) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL11455193 | 0.82 | OPRM1 (0.46) | IKZF2KDM1AMAOAOPRM1OPRL1 | |
| SCHEMBL27010641 | 0.80 | MAOA (0.47) | KDM1AMAOAKMT2A | |
| SCHEMBL8079394 | 0.79 | KDM1A (0.44) | IKZF2KDM1AMAOAOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | IKZF2 2942/4885KDM1A 455/4885MAOA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.